BOBULSKY SUSAN 4
4 · Adaptive Biotechnologies Corp · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies (ADPT) CCO Susan Bobulsky Receives Award
What Happened
Susan Bobulsky, Chief Commercial Officer (MRD) of Adaptive Biotechnologies (ADPT), received two equity awards on 2026-03-04: 59,375 shares and 62,500 shares (transaction code A — grant/award). Both awards were reported with an acquisition price of $0.00, for a total of 121,875 shares granted. The Form 4 was filed on 2026-03-06.
Key Details
- Transaction date(s): 2026-03-04 (filed 2026-03-06). Filing appears timely under the two-business-day Form 4 rule.
- Awards: 59,375 shares (A) and 62,500 shares (A); price reported $0.00 for each grant.
- Total shares awarded: 121,875.
- Shares owned after transaction: Not specified in the filing.
- Notable footnotes: None disclosed on the filing; no 10b5-1, tax withholding, or cashless exercise indicated.
- Filing timeliness: Not marked late.
Context
Transaction code A indicates these are grants/awards (typically equity compensation such as restricted stock or RSUs being issued), not open-market purchases or sales. Such awards are part of executive compensation and do not by themselves signal a buy/sell decision in the market.
Insider Transaction Report
- Award
Common Stock
2026-03-04+59,375→ 406,613 total - Award
Common Stock
2026-03-04+62,500→ 469,113 total